This study will evaluate the effect of counseling plus Approach Bias Modification on cannabis use and craving in people with cannabis use disorder. The study consists of a screening visit, four treatment visits and a follow-up. Participants will have 4 sessions of counseling, 4 sessions of Approach Bias Modification, and 3 cue reactivity sessions.
The purpose of this study is to develop repetitive transcranial magnetic stimulation (rTMS) as a potential treatment for nicotine addiction. Repetitive TMS is a non-invasive technique that uses magnetic pulses to temporarily stimulate specific brain areas in awake people (without the need for surgery, anesthetic, or other invasive procedures). This study will test whether rTMS over the forehead can produce a reduction in brain activity associated with craving that may prompt you to want to smoke cigarettes.
The purpose of this study is to evaluate the potential mechanism of action and the safety of GET73, a new drug under development for the reduction of craving and drinking in alcohol dependent individuals. The study involves five to six visits over a three to four week period, including one to two assessment visits and two visits during which participants will be assigned to take, in a double-blinded fashion, both GET73 and a placebo (two visits during each condition). During three of these visits, participants will undergo a one-hour MRI scan. Compensation is available for qualified participants.
This study examines the effects of the FDA-approved medication Gabapentin among individuals with Bipolar Disorder who smoke marijuana. Participants in the study will take Gabapentin and matched placebo (one at a time) for 5 days each. There are 5 study visits, including 2 MRI scans.
The purpose of the study is to explore the effects of progesterone on cannabis withdrawal in women who regularly smoke marijuana. Participants will be asked to abstain from marijuana use for 5 days after the onset of menses. They will receive 8 doses of either progesterone or placebo during this time. On Days 1 and 5 they will come to the clinic to complete study assessments and provide urine, saliva and blood samples.On Days 2-4 assessments will be completed via text messages, Redcap surveys and video calls. Participants will be monitored for adverse events and cannabis withdrawal on each study day.
This study examines the effects of the medication gabapentin and the supplement n-acetylcysteine among individuals with Bipolar Disorder who regularly drink alcohol. Participants in this study will take gabapentin, n-acetylcysteine, and matched placebo (one at a time) for 5 days each. There are 8 study visits, including 3 MRI scans.
This study is designed to evaluate the safety and effectiveness of using two different medications (extended release naltrexone and bupropion) compared to matching placebo (an inactive substance) in the treatment of methamphetamine use disorder. Participants will receive study medications along with brief medication management for twelve weeks, with follow up visits at weeks 13 and 16.
This study aims to conduct focus groups with adolescents and parents (30 adolescents and 30 parents) to gather feedback to help design an integrated psychological therapy for co-occurring PTSD and substance use among adolescents (Teen COPE). This information will be used to make revisions to the new Teen COPE Therapist Guide and Patient Workbook.
The purpose of this study is to understand factors contributing to managing emotions, behavior problems, and substance use risk among girls. Middle school adolescent girls will be asked about their thoughts and feelings about themselves and their ethnic group, perceptions, and discrimination. They will also report on their behavior and substance use risk. Their reactions to recent incidents of unfair treatment or disciplinary action will also be assessed.
This study will examine the effect of N-Acetylcysteine (NAC), an over-the-counter antioxidant supplement on brains of youth (ages 15-19) using magnetic resonance imaging (MRI). 55 adolescents will receive, in a counterbalanced order, a 10-day course of NAC 1200 mg twice daily and a subsequent 10-day course of matched placebo twice daily, separated by 11 days. Urine samples will be collected at screening and urine and blood samples will be collected before and after each course of medication treatment. Participants will receive a 1- hour MRI scan at baseline and after each treatment trial.
You/your child could be eligible to participate if he or she is:
Between the ages of 15 and 19.
May or may not drink alcohol.
Participants must provide informed consent and youth under 18 must have parental consent to participate.
Compensation is available to those who qualify.